Gilead to acquire HanChenXingTai oral IL-23R program HCXT-2001 for $1.275 billion upfront

Gilead Sciences announced on October 22 that it has signed a definitive agreement with HanChenXingTai to acquire global rights to its oral IL-23R inhibitor program for a $1.275 billion all-cash upfront payment. The core asset, HCXT-2001, is in Phase I clinical trials, and the transaction is expected to close in the fourth quarter of 2026.